Last reviewed · How we verify
Atriopeptin (CARPERITIDE)
Atriopeptin (generic name: CARPERITIDE) is a carperitide drug. It is currently in Phase 3 development.
Carperitide works by mimicking the action of a naturally occurring hormone that helps to relax blood vessels and reduce blood pressure.
Atriopeptin, also known as carperitide, is a small molecule drug that targets the atrial natriuretic peptide receptor 1. It is used to treat certain heart conditions, although its exact approved indications are unknown. As a carperitide, it is a synthetic version of a naturally occurring peptide hormone. The commercial status of carperitide is unclear, and it may not be available as a generic medication. Key safety considerations include its short half-life of 0.22 hours.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CARPERITIDE |
|---|---|
| Drug class | carperitide |
| Target | Atrial natriuretic peptide receptor 1, Atrial natriuretic peptide receptor 1 |
| Modality | Recombinant protein |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Imagine your blood vessels are like a tight rubber band. When they're too tight, it's hard for blood to flow through. Carperitide helps to relax these blood vessels, making it easier for blood to flow and reducing the pressure on your heart.
Approved indications
Common side effects
- Cardiac failure
- Renal impairment
- Hypernatraemia
- Hepatic function abnormal
- Cerebral infarction
Key clinical trials
- Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure (PHASE2)
- The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure (PHASE4)
- Carperitide in Acute Respiratory Distress Syndrome (ARDS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atriopeptin CI brief — competitive landscape report
- Atriopeptin updates RSS · CI watch RSS
Frequently asked questions about Atriopeptin
What is Atriopeptin?
How does Atriopeptin work?
What is the generic name of Atriopeptin?
What drug class is Atriopeptin in?
What development phase is Atriopeptin in?
What are the side effects of Atriopeptin?
What does Atriopeptin target?
Related
- Drug class: All carperitide drugs
- Target: All drugs targeting Atrial natriuretic peptide receptor 1, Atrial natriuretic peptide receptor 1
- Therapeutic area: All drugs in Cardiovascular
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing